Hexarelin

Synthetic GH-secretagogue hexapeptide

GH-axis and neuroendocr…

Hexarelin

Evidence levelLimited human

Human evidenceLimited

Regulatory statusNo FDA/EMA approval identified

What you need to know in 20 seconds

What is it?	Synthetic GH-secretagogue hexapeptide
Research focus	GH-axis and neuroendocrine research
Human evidence	Small human dose-response studies show GH release plus prolactin/cortisol effects; an overnight study reported reduced selected slow-wave/stage-4 sleep measures despite endocrine stimulation.
Regulatory status	No FDA/EMA-approved hexarelin medicine identified.
Main limitations	Body-composition, recovery, performance, sleep or longevity benefit.
Safety	Endocrine spillover includes prolactin, ACTH and cortisol effects; long-term safety is not established.

Small human dose-response studies show GH release plus prolactin/cortisol effects; an overnight study reported reduced selected slow-wave/stage-4 sleep measures despite endocrine stimulation.

What the evidence actually supports

✓Endocrine target engagement must not be marketed as proven body-composition benefit.
✓Add to safety/unknowns and secretagogue comparisons.
✓Useful negative/counterintuitive outcome for recovery-focused pages.

What is not established / key limitations

×No controlled evidence here for physique, recovery or anti-ageing outcomes.
×No evidence this improves body composition, injury recovery or longevity.
×Sleep architecture worsened on selected measures in this experiment.

Selected study & evidence records

Hexarelin GH response in healthy men

1994 · Placebo-controlled dose-response study · n=12

Hexarelin produced dose-dependent GH release.

Study detail → Primary source ↗

Hexarelin-induced GH, cortisol and prolactin release: dose-response study

1996 · Dose-response human physiology study · n=Small study

Hexarelin produced dose-dependent GH and prolactin responses and a cortisol increase at higher doses; low-dose hexarelin was synergistic with GHRH for GH release.

Study detail → Primary source ↗

Hexarelin decreases slow-wave sleep and stimulates multiple hormones during sleep

2004 · Placebo-controlled sleep/endocrine study · n=7

Hexarelin reduced stage-4/slow-wave-related sleep measures while increasing GH, prolactin, ACTH and cortisol.

Study detail → Primary source ↗

Safety and unknowns

Endocrine spillover includes prolactin, ACTH and cortisol effects; long-term safety is not established.

Repeated endocrine stimulation may affect other pituitary hormones; long-term lifestyle-use safety is not established.

Technical details

Mechanism / biologyGHS receptor agonist producing strong GH release and also effects on prolactin/ACTH/cortisol.

Route / formulation boundaryAcute GH release is a pharmacodynamic finding, not proof of body-composition or anti-ageing benefit.

Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.

Dosing evidence statusVerified dosing evidence added. Published human dose-response regimens. See dosing_evidence records for route, regimen, population, duration and source.

Identifiers & alternate namesExamorelin · Hex